BridgeMD
New treatment option for Alzheimer Disease
Official title Advantage of Cerebellar Transcranial Magnetic Stimulation in Alzheimer's Diseases （ACT-AD）
ClinicalTrials.gov ID: NCT06669182
What this study is testing
- What it's testing
- Alzheimer's Disease (AD) is the primary cause of dementia, with its prominent feature being cognitive decline. The cerebellum plays a crucial role in cognitive processing, making it a potential target for therapeutic intervention.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 50 to 85
You may be able to join if
- Age: 50-85 years old
- Meet the core clinical criteria of NIA-AA for possible Alzheimer's disease dementia, and PET or cerebrospinal fluid markers show elevated p-tau and...
- MMSE score ranges from 18-26 points; CDR score 0.5-1 points
- The patient has received treatment with acetylcholinesterase inhibitors (AChEI), NMDA receptor antagonists, or mannequine therapy, and the current...
- At least one adult caregiver
You likely can't join if
- Neurodegenerative disorders other than AD.
- Significant intracranial focal or vascular pathology seen on brain MRI scan
- History of seizure (with the exception of febrile seizures in childhood)
- Any of the following psychotic disorders (DSM IV-TR criteria):
- Major depressive disorder (current)
- Schizophrenia
See the full eligibility criteria
- Age: 50-85 years old
- Meet the core clinical criteria of NIA-AA for possible Alzheimer's disease dementia, and PET or cerebrospinal fluid markers show elevated p-tau and decreased A β (1-42)
- MMSE score ranges from 18-26 points; CDR score 0.5-1 points
- The patient has received treatment with acetylcholinesterase inhibitors (AChEI), NMDA receptor antagonists, or mannequine therapy, and the current dosing regimen has remained stable for the 12 weeks prior to baseline...
- At least one adult caregiver
- The patient or legal guardian voluntarily signs the informed consent form
- Neurodegenerative disorders other than AD.
- Significant intracranial focal or vascular pathology seen on brain MRI scan
- History of seizure (with the exception of febrile seizures in childhood)
- Any of the following psychotic disorders (DSM IV-TR criteria):
- Major depressive disorder (current)
- Schizophrenia
- Other psychotic disorders, bipolar disorder, or substance related disorders (within the past 5 years)
- GDS score ≥ 8 points in baseline assessment
- Cerebrovascular disease, severe infection, malignant tumor, or severe dysfunction of organs such as heart, liver, and kidney.
- Pregnant or lactating women
- Contraindications for TMS or MRI, metal or implanted devices in the body (such as pacemakers, deep brain stimulators).
- Participate in AD related clinical trials within 6 months prior to research registration
The study team makes the final eligibility decision.
Where it's taking place
- Xi'an, Shaanxi, China
- Xi'an, Shannxi, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 50 years to 85 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Xi'an, Shaanxi, China; Xi'an, Shannxi, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.